Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.71 |
| ▸ | P4HB | P07237 | 5/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | XDH | P47989 | 4/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.71 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CA4 | P22748 | 2/20 | 0.71 |
| ▸ | CA7 | P43166 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 7/20 | 0.69 |
| ▸ | POLB | P06746 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | ALPI | P09923 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reynoutrin SCHEMBL31130799 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL14350762 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL3641504 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL4226891 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL38138 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL20298285 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Guajaverin SCHEMBL3635416 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL6759025 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL6119167 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL28550462 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116138489-A | Application of lotus leaf extract in reducing nitrosamine content in tobacco | 湖北省烟草科学研究院 | 2023-05-23 | — | — | CN | claimed |
| EP-2976061-B1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD (BE) | 2019-10-16 | — | — | EP | claimed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | claimed |
| CN-114113348-B | Preparation method of standard rose decoction, characteristic spectrum and content determination method | 国药集团同济堂（贵州）制药有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116138489-A | Application of lotus leaf extract in reducing nitrosamine content in tobacco | 湖北省烟草科学研究院 | 2023-05-23 | — | — | CN | disclosed |
| CN-114113348-A | Preparation method, characteristic spectrum and content determination method of rose standard decoction | 国药集团同济堂（贵州）制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-2976061-B1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD (BE) | 2019-10-16 | — | — | EP | disclosed |
| US-20190216704-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2019-07-18 | — | — | US | disclosed |
| US-20160279043-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2016-09-29 | — | — | US | disclosed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-8337909-B2 | Process of extracting procyanidins by alkaline hydrolysis | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110301232-A1 | PROCESS OF EXTRACTING PROCYANIDINS BY ALKALINE HYDROLYSIS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2011-12-08 | — | — | US | disclosed |
| JP-2007106725-A | COMPOSITION FOR AMELIORATING MOOD DISORDER | MARUZEN PHARMACEUT CO LTD | 2007-04-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216704-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | SIRT3, NNT, SIRT1 | KDM4E 3614/4885AKR1B1 4328/4885P4HB 1132/4885 |
| US-20160279043-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | SIRT3, NNT, SIRT1 | KDM4E 3614/4885AKR1B1 4328/4885P4HB 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.